Strides Pharma Science Ltd Q3 FY2023 consolidated loss at Rs. 80.02 crores

Strides Pharma Science Limited has reported Consolidated financial results for the period ended December 31, 2022.

Financial Results (Q3 FY2023) - QoQ Comparison

The company has reported total income of Rs. 891.046 crores during the period ended December 31, 2022 as compared to Rs. 920.556 crores during the period ended September 30, 2022.

The company has posted net profit / (loss) of Rs. -80.026 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 22.825 crores for the period ended September 30, 2022.

The company has reported EPS of Rs. -8.86 for the period ended December 31, 2022 as compared to Rs. 2.54 for the period ended September 30, 2022.

Financials	Q3 FY2023	Q2 FY2023	% Change
Total Income	₹891.046 crs	₹920.556 crs	-3.21%
Net Profit	₹-80.026 crs	₹22.825 crs	-450.61%
EPS	₹-8.86	₹2.54	-448.82%

Financial Results (Q3 FY2023) - YoY Comparison

The company has reported total income of Rs.891.046 crores during the period ended December 31, 2022 as compared to Rs.804.582 crores during the period ended December 31, 2021.

The company has posted net profit / (loss) of Rs.-80.026 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.-121.671 crores for the period ended December 31, 2021.

The company has reported EPS of Rs.-8.86 for the period ended December 31, 2022 as compared to Rs.-13.55 for the period ended December 31, 2021.

Financials	Q3 FY2023	Q3 FY2022	% Change
Total Income	₹891.046 crs	₹804.582 crs	10.75%
Net Profit	₹-80.026 crs	₹-121.671 crs	34.23%
EPS	₹-8.86	₹-13.55	34.61%

Financial Results (9 Months Ended FY2023) - YoY Comparison

The company has reported total income of Rs.2765.224 crores during the 9 Months period ended December 31, 2022 as compared to Rs.2250.163 crores during the 9 Months period ended December 31, 2021.

The company has posted net profit / (loss) of Rs.-193.093 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.-489.430 crores for the 9 Months period ended December 31, 2021.

The company has reported EPS of Rs.-21.45 for the 9 Months period ended December 31, 2022 as compared to Rs.-54.54 for the 9 Months period ended December 31, 2021.

Financials	9 Months Ended FY2023	9 Months Ended FY2022	% Change
Total Income	₹2765.224 crs	₹2250.163 crs	22.89%
Net Profit	₹-193.093 crs	₹-489.430 crs	60.55%
EPS	₹-21.45	₹-54.54	60.67%

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 318.50 as compared to the previous close of Rs. 336.65. The total number of shares traded during the day was 139245 in over 4915 trades.

The stock hit an intraday high of Rs. 349.50 and intraday low of 314.25. The net turnover during the day was Rs. 46895928.00.

Source : Equity Bulls

Keywords

StridesPharmaScience Q3FY23 9MFY23 ResultUpdate